Noladin ether | Enzo Life Sciences BML-FA033-0005 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Noladin ether

catalog :

BML-FA033-0005

quantity :

5 mg

citations: 10

Reference
Mahadevan A, Razdan R. Further advances in the synthesis of endocannabinoid-related ligands. AAPS J. 2005;7:E496-502 pubmed
Shoemaker J, Ruckle M, Mayeux P, Prather P. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther. 2005;315:828-38 pubmed
Shoemaker J, Joseph B, Ruckle M, Mayeux P, Prather P. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther. 2005;314:868-75 pubmed
Avraham Y, Menachem A, Okun A, Zlotarav O, Abel N, Mechoulam R, et al. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Brain Res Bull. 2005;65:117-23 pubmed
Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, Hillard C, et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64:8826-30 pubmed
Duncan M, Millns P, Smart D, Wright J, Kendall D, Ralevic V. Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. Br J Pharmacol. 2004;142:509-18 pubmed
Appendino G, Ligresti A, Minassi A, Daddario N, Bisogno T, Di Marzo V. Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB(1) receptors. Bioorg Med Chem Lett. 2003;13:43-6 pubmed
Laine K, Jarvinen K, Mechoulam R, Breuer A, Jarvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci. 2002;43:3216-22 pubmed
Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 2002;513:294-8 pubmed
Hanus L, Abu Lafi S, Fride E, Breuer A, Vogel Z, Shalev D, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001;98:3662-5 pubmed

product information

Product ID :

BML-FA033

Catalog Number :

BML-FA033-0005

Product Name :

Noladin ether

Product Type :

Biochemical

Size :

5 mg

list of Pubmed id :

16353927, 16081674, 15901805, 15763177, 15604240, 15148262, 12467613, 12356827, 11904167, 11259648

Product Description :

Endogenous cannabinoid agonist isolated from porcine brain. Binds specifically to CB1 (Ki=21.2nM) and CB2 (Ki=>3µM) receptors. Causes sedation hypothermia, intestinal immobility and mild antinociception in mice. Chemically stable, but less potent than 2-arachidonoylglycerol (Prod. No. BML-FA028) with an endogenous half-life time of hours rather than minutes.

ALTnames :

2-Arachidonyl glyceryl ether, 2-AG ether, 5Z,8Z,11Z,14Z-Eicosatetraen-2-glyceryl ether

Purity :

≥98% (TLC)

Storage :

-20°C